Torahito A. Gao

Torahito A. Gao

Auto-generated profile, based on publicly available information

Torahito A. Gao

University of California, Los Angeles 1 Department of Chemical and Biomolecular Engineering Los Angeles, California

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJustin D. Clubb
Justin D. Clubb
TGTorahito A. Gao
Torahito A. Gao
YCYvonne Y. Chen
Yvonne Y. Chen
The advent of modern synthetic-biology tools has enabled the development of cellular treatments with engineered specificity, leading to a new paradigm in anticancer immunotherapy. T cells have been at the forefront of such development, with six chimeric antigen receptor–modified T-cell products approved by the FDA for the treatment of hematologic malignancies in the last 5 years. Natural killer (NK) cells are innate lymphocytes with potent cytotoxic activities, and they have become an increasingly attractive alternative to T-cell therapies due to their potential for allogeneic, “off-the-shelf” applications. However, both T cells and NK cells face numerous challenges, including antigen escape, the immunosuppressive tumor microenvironment, and potential for severe toxicity. Many synthetic-biology strategies have been developed to address these obstacles, most commonly in the T-cell context. In this review, we discuss the array of strategies developed to date, their application in the NK-cell context, as well as opportunities and challenges for clinical translation.

4 March 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
TGTorahito A. Gao
Torahito A. Gao
RSRyan M. Shih
Ryan M. Shih
JCJustin D. Clubb
Justin D. Clubb
SHShao-Hsi Hung
Shao-Hsi Hung
TSTanya Singh
Tanya Singh
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR) T cell therapy has shown limited efficacy against solid tumors, which often reside in highly immunosuppressive tumor microenvironments (TMEs). TMEs can be highly abundant in vascular endothelial growth factor A (VEGF), which contributes to immunosuppression and abnormal tumor vasculature. Here, we found that CAR T cells engineered to secrete an anti-VEGF single-chain variable fragment (CAR-αVEGF T cells) achieved superior antitumor efficacy against multiple in vivo models of ovarian cancer and glioma, outperforming conventional CAR T cells with and without combination anti-VEGF antibody therapy. Microscopy, flow cytometry, and transcriptomic analyses revealed that armoring the CAR T cells with anti-VEGF single-chain variable fragments enhanced their activation and mitochondrial fitness and enriched immune-stimulatory signatures among endogenous immune cells in the tumor-bearing brain. Moreover, CAR-αVEGF T cells circumvented multiple detrimental effects associated with on-target CAR T cell therapy, including infiltration of suppressive myeloid cells, exaggerated vasculature abnormalities, and hypoxia. Together, our results provide rationale for the clinical translation of CAR-αVEGF T cells as a safe and potent therapy for solid tumors characterized by elevated VEGF.

8 June 2026 in Cancer Research
Verified
Journal Article
Closed access
JCJustin D. Clubb
Justin D. Clubb
RSRyan M. Shih
Ryan M. Shih
TGTorahito A. Gao
Torahito A. Gao
ASAmanda Shafer
Amanda Shafer
SVShreya Vajragiri
Shreya Vajragiri
YCYvonne Y. Chen
Yvonne Y. Chen
Chimeric antigen receptor (CAR) T-cell therapy has shown early promise against glioblastoma, which lacks effective treatment options. However, two key challenges curtail efficacy: tumor-antigen heterogeneity and an immunosuppressive tumor microenvironment. CAR T cells engineered to secrete combinations of immunomodulatory proteins can reverse immune suppression and engage endogenous immunity. Through head-to-head in vivo comparisons of potentially synergistic armor combinations, we demonstrated that T cells expressing a CAR plus IL12 and the decoy-resistant form of IL18 (CAR-12.DR18 T cells) show strong efficacy against antigen-heterogeneous glioma in immunocompetent mice. Robust antitumor efficacy with effective toxicity mitigation was achieved via combined administration of CAR-12.DR18 T cells with CAR T cells that secrete an anti–vascular endothelial growth factor (anti-VEGF) single-chain variable fragment (scFv). This combination therapy presents a clinically applicable strategy to overcome key barriers to the effective treatment of glioblastoma. Significance: CAR-T cells armored with cytokines and anti-VEGF single-chain variable fragments can control orthotopic, antigen-heterogeneous glioma with minimal toxicity, providing a therapeutic strategy for glioblastoma patients in urgent need of efficacious treatments.

4 August 2026
Verified
Other
Open access
PDF file
JCJustin D. Clubb
Justin D. Clubb
RSRyan M. Shih
Ryan M. Shih
TGTorahito A. Gao
Torahito A. Gao
ASAmanda Shafer
Amanda Shafer
SVShreya Vajragiri
Shreya Vajragiri
YCYvonne Y. Chen
Yvonne Y. Chen
Fig. S9. CAR-T cells are rare in the organs of mice treated with cytokine-armored CAR-T cells.

4 August 2026
Verified
Other
Open access
PDF file
JCJustin D. Clubb
Justin D. Clubb
RSRyan M. Shih
Ryan M. Shih
TGTorahito A. Gao
Torahito A. Gao
ASAmanda Shafer
Amanda Shafer
SVShreya Vajragiri
Shreya Vajragiri
YCYvonne Y. Chen
Yvonne Y. Chen
Fig. S13. H&E staining of mouse brains 7 days after ATC.

4 August 2026
Verified
Other
Open access
PDF file
JCJustin D. Clubb
Justin D. Clubb
RSRyan M. Shih
Ryan M. Shih
TGTorahito A. Gao
Torahito A. Gao
ASAmanda Shafer
Amanda Shafer
SVShreya Vajragiri
Shreya Vajragiri
YCYvonne Y. Chen
Yvonne Y. Chen
Table S2. Genes included in AUCell antigen-presentation genes score.